|1.||Bonfil, R D: 1 article (03/2001)|
|2.||Finney, R E: 1 article (09/2000)|
|3.||Nudelman, E: 1 article (09/2000)|
|4.||Klein, P: 1 article (09/2000)|
|5.||Wang, N: 1 article (09/2000)|
|6.||Waggoner, D: 1 article (09/2000)|
|7.||Bursten, S: 1 article (09/2000)|
|8.||Lewis, R A: 1 article (09/2000)|
|9.||White, T: 1 article (09/2000)|
|10.||Leer, L L: 1 article (09/2000)|
09/15/2000 - "In this report, it has been demonstrated that enhanced phospholipid metabolism through PA in tumor cells can be exploited pharmacologically for development of anticancer agents, such as CT-2584, a cancer chemotherapeutic drug candidate currently in Phase II clinical trials. "
09/15/2000 - "We conclude that CT-2584 effects a novel mechanism of cytotoxicity to cancer cells, involving a specific modulation of phospholipid metabolism."
03/01/2001 - "CT-2584, an anticancer agent that inhibits phospholipid signaling, is under development by Cell Therapeutics Inc (CTI) as a potential treatment for various types of cancer. "
01/01/1997 - "Lastly, we found that B/1 cells were more resistant to a novel chemotherapeutic agent CT-2584, which appears to kill tumor cells by stimulating production of reactive oxygen intermediates in mitochondria. "
11/01/1997 - "In vivo, CT-2584 significantly reduced tumor growth in SCID mice bearing Alex 0 or 0.5 xenografts as determined by serial measurements of HBsAg. "
|5.||Hepatitis B Surface Antigens (HBsAg)
|1.||Heterologous Transplantation (Xenotransplantation)